Please enable JavaScript to continue using this application.

Compare $GNLX vs $UNCY | Chartloom

Compare

$GNLX vs $UNCY

Genelux Corp · Unicycive Therapeutics Inc

GNLX

Genelux Corp

UNCY

Unicycive Therapeutics Inc

Compare $GNLX vs $UNCY

Comparing Genelux Corp and Unicycive Therapeutics Inc

GNLXGenelux Corp

UNCYUnicycive Therapeutics Inc

GNLXGenelux Corp

Market cap

$115M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-43.7%

52W performance

-46.1%

FCF yield

-25.0%

UNCYUnicycive Therapeutics Inc

Market cap

$110M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.31x

Rev growth (TTM)

—

YTD performance

-29.1%

52W performance

-13.8%

FCF yield

-25.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GNLX

UNCY

Detailed metrics comparison

GNLX

Genelux Corp

UNCY

Unicycive Therapeutics Inc

Market Cap

GNLX$115M

UNCY$110M

Enterprise Value

GNLX$106M

UNCY$66M

Price

GNLX$2.56

UNCY$4.11

P/E Ratio

GNLXN/A

UNCYN/A

P/S Ratio

GNLX14,348.80x

UNCY31.15x

EV/Sales

GNLX13,200.80x

UNCY0.00x

EV/EBITDA

GNLX0.00x

UNCY0.00x

P/B Ratio

GNLX7.19x

UNCY2.21x

P/FCF Ratio

GNLXN/A

UNCYN/A

EV/FCF

GNLX-3.68x

UNCY-2.35x

PEG Ratio

GNLXN/A

UNCYN/A

Forward P/E (NTM)

GNLXN/A

UNCYN/A

Forward P/S (NTM)

GNLXN/A

UNCY0.31x

Revenue (TTM)

GNLX$8K

UNCY$0

Revenue Growth (YoY)

GNLXN/A

UNCYN/A

Forward Rev Growth

GNLX551.6%

UNCY37378.0%

Gross Margin (TTM)

GNLX0.0%

UNCY0.0%

Operating Margin (TTM)

GNLX0.0%

UNCY0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

UNCY0.0%

Net Margin (TTM)

GNLX-444950.0%

UNCY0.0%

FCF Margin (TTM)

GNLX-358537.5%

UNCYN/A

Net Income (TTM)

GNLX$-36M

UNCY$-35M

FCF (TTM)

GNLX$-29M

UNCY$-28M

EPS (TTM)

GNLX-$0.79

UNCY-$1.31

ROE (TTM)

GNLX-20585.0%

UNCY-8881.0%

ROA (TTM)

GNLX-13879.0%

UNCY-5966.0%

ROIC (TTM)

GNLX-20585.0%

UNCY-8881.0%

Cash

GNLX$9M

UNCY$44M

Debt

GNLX$0

UNCY$0

Net Cash/Debt

GNLX$9M

UNCY$44M

Current Ratio (TTM)

GNLX2.39x

UNCY3.81x

Quick Ratio (TTM)

GNLX2.33x

UNCY3.28x

Debt/Equity (TTM)

GNLX0.00x

UNCY0.00x

Debt/Assets (TTM)

GNLX0.0%

UNCY0.0%

Interest Coverage (TTM)

GNLXN/A

UNCYN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

UNCY0.00x

Beta

GNLX0.56

UNCY1.78

52W Performance

GNLX-46.1%

UNCY-13.8%

YTD Performance

GNLX-43.7%

UNCY-29.1%

% from 52W High

GNLX-70.0%

UNCY-53.0%

% from 52W Low

GNLX11.8%

UNCY4.6%

Asset Turnover (TTM)

GNLX0.00x

UNCY0.05x

FCF Yield (TTM)

GNLX-25.0%

UNCY-25.4%

Earnings Yield (TTM)

GNLX-31.0%

UNCY-32.1%

Dividend Yield (TTM)

GNLXN/A

UNCYN/A

Rule of 40

GNLX-358,537.5

UNCY0.0

EV/GP/RG

GNLXN/A

UNCYN/A

Ticker research

View GNLX research View UNCY research

Metric	GNLX Genelux Corp	UNCY Unicycive Therapeutics Inc
Market & Valuation
Market Cap	$115M	$110M
Enterprise Value	$106M	$66M
Price	$2.56	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	31.15x
EV/Sales	13,200.80x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	2.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-2.35x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.31x
Revenue & Growth
Revenue (TTM)	$8K	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	551.6%	37378.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	0.0%
Net Margin (TTM)	-444950.0%	0.0%
FCF Margin (TTM)	-358537.5%	N/A
Net Income (TTM)	$-36M	$-35M
FCF (TTM)	$-29M	$-28M
EPS (TTM)	-$0.79	-$1.31
ROE (TTM)	-20585.0%	-8881.0%
ROA (TTM)	-13879.0%	-5966.0%
ROIC (TTM)	-20585.0%	-8881.0%
Financial Health
Cash	$9M	$44M
Debt	$0	$0
Net Cash/Debt	$9M	$44M
Current Ratio (TTM)	2.39x	3.81x
Quick Ratio (TTM)	2.33x	3.28x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	1.78
52W Performance	-46.1%	-13.8%
YTD Performance	-43.7%	-29.1%
% from 52W High	-70.0%	-53.0%
% from 52W Low	11.8%	4.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-25.0%	-25.4%
Earnings Yield (TTM)	-31.0%	-32.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View UNCY research

Valuation

P/S Ratio

UNCY

31.15x

GNLX

14,348.80x

EV/FCF

GNLX

-3.68x

UNCY

-2.35x

Growth & revenue

Forward Revenue Growth

UNCY

37378.0%

GNLX

551.6%

Profitability & performance

Gross Margin

GNLX

0.0%

UNCY

0.0%

ROE

UNCY

-8881.0%

GNLX

-20585.0%

FCF Yield %

GNLX

-25.0%

UNCY

-25.4%

52-Week Performance

UNCY

-13.8%

GNLX

-46.1%

Detailed metrics comparison

GNLX

Genelux Corp

UNCY

Unicycive Therapeutics Inc

Market Cap

GNLX$115M

UNCY$110M

Enterprise Value

GNLX$106M

UNCY$66M

Price

GNLX$2.56

UNCY$4.11

P/E Ratio

GNLXN/A

UNCYN/A

P/S Ratio

GNLX14,348.80x

UNCY31.15x

EV/Sales

GNLX13,200.80x

UNCY0.00x

EV/EBITDA

GNLX0.00x

UNCY0.00x

P/B Ratio

GNLX7.19x

UNCY2.21x

P/FCF Ratio

GNLXN/A

UNCYN/A

EV/FCF

GNLX-3.68x

UNCY-2.35x

PEG Ratio

GNLXN/A

UNCYN/A

Forward P/E (NTM)

GNLXN/A

UNCYN/A

Forward P/S (NTM)

GNLXN/A

UNCY0.31x

Revenue (TTM)

GNLX$8K

UNCY$0

Revenue Growth (YoY)

GNLXN/A

UNCYN/A

Forward Rev Growth

GNLX551.6%

UNCY37378.0%

Gross Margin (TTM)

GNLX0.0%

UNCY0.0%

Operating Margin (TTM)

GNLX0.0%

UNCY0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

UNCY0.0%

Net Margin (TTM)

GNLX-444950.0%

UNCY0.0%

FCF Margin (TTM)

GNLX-358537.5%

UNCYN/A

Net Income (TTM)

GNLX$-36M

UNCY$-35M

FCF (TTM)

GNLX$-29M

UNCY$-28M

EPS (TTM)

GNLX-$0.79

UNCY-$1.31

ROE (TTM)

GNLX-20585.0%

UNCY-8881.0%

ROA (TTM)

GNLX-13879.0%

UNCY-5966.0%

ROIC (TTM)

GNLX-20585.0%

UNCY-8881.0%

Cash

GNLX$9M

UNCY$44M

Debt

GNLX$0

UNCY$0

Net Cash/Debt

GNLX$9M

UNCY$44M

Current Ratio (TTM)

GNLX2.39x

UNCY3.81x

Quick Ratio (TTM)

GNLX2.33x

UNCY3.28x

Debt/Equity (TTM)

GNLX0.00x

UNCY0.00x

Debt/Assets (TTM)

GNLX0.0%

UNCY0.0%

Interest Coverage (TTM)

GNLXN/A

UNCYN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

UNCY0.00x

Beta

GNLX0.56

UNCY1.78

52W Performance

GNLX-46.1%

UNCY-13.8%

YTD Performance

GNLX-43.7%

UNCY-29.1%

% from 52W High

GNLX-70.0%

UNCY-53.0%

% from 52W Low

GNLX11.8%

UNCY4.6%

Asset Turnover (TTM)

GNLX0.00x

UNCY0.05x

FCF Yield (TTM)

GNLX-25.0%

UNCY-25.4%

Earnings Yield (TTM)

GNLX-31.0%

UNCY-32.1%

Dividend Yield (TTM)

GNLXN/A

UNCYN/A

Rule of 40

GNLX-358,537.5

UNCY0.0

EV/GP/RG

GNLXN/A

UNCYN/A

Ticker research

View GNLX research View UNCY research

Metric	GNLX Genelux Corp	UNCY Unicycive Therapeutics Inc
Market & Valuation
Market Cap	$115M	$110M
Enterprise Value	$106M	$66M
Price	$2.56	$4.11
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	31.15x
EV/Sales	13,200.80x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	2.21x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-2.35x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.31x
Revenue & Growth
Revenue (TTM)	$8K	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	551.6%	37378.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	0.0%
Net Margin (TTM)	-444950.0%	0.0%
FCF Margin (TTM)	-358537.5%	N/A
Net Income (TTM)	$-36M	$-35M
FCF (TTM)	$-29M	$-28M
EPS (TTM)	-$0.79	-$1.31
ROE (TTM)	-20585.0%	-8881.0%
ROA (TTM)	-13879.0%	-5966.0%
ROIC (TTM)	-20585.0%	-8881.0%
Financial Health
Cash	$9M	$44M
Debt	$0	$0
Net Cash/Debt	$9M	$44M
Current Ratio (TTM)	2.39x	3.81x
Quick Ratio (TTM)	2.33x	3.28x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	1.78
52W Performance	-46.1%	-13.8%
YTD Performance	-43.7%	-29.1%
% from 52W High	-70.0%	-53.0%
% from 52W Low	11.8%	4.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-25.0%	-25.4%
Earnings Yield (TTM)	-31.0%	-32.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View UNCY research